 |
|
|
| |
Viral Kinetics Modeling to Predict cEVR and Aid in Dose Selection Decisions for Phase-2/3 Clinical Trials: ACH3102+ Sovaprevir, ACH2684
|
| |
| |
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
Atul Agarwal, Bao Zhang, Heather Robison, Lisa Robarge, Yongsen Zhao, Joanne Fabrycki, Dharaben Patel, Guangwei Yang, Mingjun Huang,
James Hui, Hetal Kocinsky, Elizabeth Olek, Milind Deshpande
Achillion Pharmaceuticals, Inc., New Haven, CT
|
| |
|
|
|
|
|
